Sclerosis Centre Of Catalonia Cemcat At Vall News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CHMP Favors Kesimpta for Adults With Relapsing MS in Europe
5
(8)
A branch of the European Medicines Agency (EMA) has recommended that Kesimpta (ofatumumab) be approved and made available to treat relapsing forms of multiple sclerosis (MS) in adults with active disease.
A final decision from the European Commission (EC) is expected in about two months. Typically, the EC follows opinions by the EMA’s Committee for Medicinal Products for Human Use (CHMP), which issued the recommendation.
“The positive CHMP opinion for Kesimpta underscores its potential to provide people living with [relapsing] MS in Europe with a new treatment that combines powerful efficacy with a favorable safety profile and can be taken at home,” Marie-France Tschudin, president of Novartis Pharmaceuticals, Kesimpta’s developer, said in a press release. ....

United States , Sanofi Genzyme , Xavier Montalban , Hebron University Hospital , European Commission , Leiden University Medical Center , Novartis Pharmaceuticals , Society Of America , University Of Pittsburgh , European Medicines Agency , Sclerosis Centre Of Catalonia Cemcat At Vall , Committee For Medicinal Products Human Use , Medicinal Products , Human Use , France Tschudin , Multiple Sclerosis Centre , Molecular Pathology , Medical Microbiology , Infectious Diseases , Applied Biology , Instituto De Medicina Molecular , ஒன்றுபட்டது மாநிலங்களில் , ஐயேவியர் மோன்டல்பன் , ஹெப்ரான் பல்கலைக்கழகம் மருத்துவமனை , ஐரோப்பிய தரகு , நோவர்த்திச் மருந்துகள் ,